Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 252.7KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons.
Download (PDF, 175.4KB) -
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
At least two million doses of long-acting cabotegravir for PrEP to be made available in 2025-2026.
Download (PDF, 99.2KB) -
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion
Marketing authorisation in EU expected by November 2024.
Download (PDF, 176.5KB) -
Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
GSK confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell and Annette Hughes.
Download (PDF, 138.1KB) -
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials.
Download (PDF, 204.8KB) -
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma
Granted based on results from phase III head-to-head DREAMM-7 trial.
Download (PDF, 136.8KB) -
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Data support progression to phase III clinical trials.
Download (PDF, 128.7KB) -
GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial
Results show that GSK3943104 did not meet the study’s primary efficacy objective.
Download (PDF, 121.3KB) -
Statement: Zantac (ranitidine) litigation – Dixon case
GSK confirmed it has reached a settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court.
Download (PDF, 112.0KB) -
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered statistically significant and clinically meaningful reduction in exacerbations
Download (PDF, 185.7KB) -
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announces positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) in adults with COPD.
Download (PDF, 170.6KB) -
GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress
Presenting 56 abstracts to advance scientific understanding and support ambition to improve the lives of people with respiratory conditions
Download (PDF, 168.7KB) -
European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Authorisation helps protect this population for the first time ahead of this RSV season
Download (PDF, 391.3KB) -
GSK’s Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps
Nucala is the first and only biologic in Japan with a four-weekly dosing schedule for this condition
Download (PDF, 255.2KB) -
Bepirovirsen granted SENKU designation in Japan for chronic hepatitis B
Designation expedites review of bepirovirsen as a potential treatment for people living with chronic hepatitis B (CHB)
Download (PDF, 188.9KB) -
Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Download (PDF, 123.0KB) -
GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer
Regulatory designation based on promising early clinical evidence observed with GSK5764227 in this tumour type
Download (PDF, 141.5KB) -
Statement: Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Download (PDF, 124.1KB)
